Versor Investments LP Buys Shares of 1,597 Medpace Holdings, Inc. $MEDP

Key Points

• Versor Investments LP acquired 1,597 shares of Medpace Holdings, Inc. (NASDAQ:MEDP), valued at approximately $487,000, during the first quarter, highlighting growing institutional interest in the company.
• Recent insider trading saw CFO Kevin M. Brady and President Jesse J. Geiger selling significant portions of their shares, with Geiger's sale amounting to approximately $18.9 million.
• Wall Street analysts have raised their price targets for Medpace, with estimates ranging from $430.00 to $510.00, indicating positive sentiment regarding the company’s future performance.

Versor Investments LP bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,597 shares of the company's stock, valued at approximately $487,000.

Several other institutional investors have also recently made changes to their positions in the business. Whittier Trust Co. raised its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares during the last quarter. Benjamin Edwards Inc. grew its position in Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock valued at $366,000 after buying an additional 36 shares during the period. Assetmark Inc. grew its position in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after buying an additional 43 shares during the period. Proficio Capital Partners LLC grew its position in Medpace by 6.4% during the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock valued at $237,000 after buying an additional 47 shares during the period. Finally, Park Avenue Securities LLC grew its position in Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after buying an additional 48 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Activity at Medpace

In related news, Director Cornelius P. Mccarthy III sold 1,662 shares of the company's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director owned 10,197 shares of the company's stock, valued at approximately $4,742,012.88. This represents a 14.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 114,450 shares of company stock worth $51,791,251 in the last 90 days. 20.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on MEDP. Barclays raised their price target on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Robert W. Baird raised their price target on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. UBS Group lowered shares of Medpace from a "neutral" rating to a "sell" rating and raised their price target for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Finally, Truist Financial raised their price target on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Medpace has an average rating of "Reduce" and an average target price of $406.60.

Medpace Stock Up 2.3%

Shares of NASDAQ MEDP traded up $10.30 during trading on Friday, hitting $463.64. The company had a trading volume of 328,935 shares, compared to its average volume of 424,882. The stock has a fifty day simple moving average of $378.86 and a two-hundred day simple moving average of $335.05. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The firm has a market capitalization of $13.02 billion, a price-to-earnings ratio of 34.47, a price-to-earnings-growth ratio of 2.92 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.